García-Cobos Silvia, Campos José, Román Federico, Carrera Cristina, Pérez-Vázquez María, Aracil Belén, Oteo Jesús
Antibiotic Laboratory, Bacteriology Service, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Antimicrob Agents Chemother. 2008 Jul;52(7):2407-14. doi: 10.1128/AAC.00214-08. Epub 2008 Apr 28.
Ampicillin resistance in Haemophilus influenzae due to alterations in penicillin-binding proteins (beta-lactamase negative ampicillin resistant [BLNAR]) is acquiring increasing clinical and epidemiological importance. BLNAR strains with low ampicillin MICs (0.5 to 4 microg/ml) represent the majority of this population in Europe and the United States, but separating them from susceptible isolates is challenging. To investigate the best method to identify low-BLNAR strains, we studied the antibiotic susceptibilities of 94 clinical isolates of H. influenzae by microdilution, Etest, and disk diffusion: 25 had no resistance mechanisms (gBLNAS), 34 had mutations in the ftsI gene only (gBLNAR), 20 were beta-lactamase producers only (gBLPAR), and 15 showed beta-lactamase production and mutations in the ftsI gene (gBLPACR). By current CLSI breakpoints, most gBLNAR isolates were ampicillin susceptible by microdilution (76.5%) or by Etest (88.2%). Most gBLNAR strains (79.4%) were nonsusceptible to amoxicillin (the most widely used community antibiotic in the United States and Europe) when tested by microdilution. By Etest, 15% of beta-lactamase-positive isolates were nonresistant to ampicillin or amoxicillin. The poorest agreement between Etest and microdilution results was for the gBLPAR isolates (25% for ampicillin, 15% for amoxicillin, and 10% for cefaclor). Low-strength disks of ampicillin and amoxicillin-clavulanic acid poorly identified low-BLNAR isolates and are not recommended as a screening method. We suggest new amoxicillin breakpoints for BLNAR isolates as follows: susceptible, MIC < or = 0.5 microg/ml (no resistance mechanisms; pharmacokinetic/pharmacodynamic [PK/PD] data favorable); intermediate, MICs = 1 to 2 microg/ml (resistance mechanisms present but PK/PD data favorable), and resistant, MICs > or = 4 microg/ml (resistance mechanisms present and PK/PD data unfavorable).
由于青霉素结合蛋白的改变导致的流感嗜血杆菌对氨苄西林耐药(β-内酰胺酶阴性氨苄西林耐药[BLNAR])在临床和流行病学上的重要性日益增加。氨苄西林最低抑菌浓度(MIC)较低(0.5至4微克/毫升)的BLNAR菌株在欧洲和美国占该群体的大多数,但将它们与敏感菌株区分开来具有挑战性。为了研究鉴定低BLNAR菌株的最佳方法,我们通过微量稀释法、Etest法和纸片扩散法研究了94株流感嗜血杆菌临床分离株的抗生素敏感性:25株没有耐药机制(gBLNAS),34株仅在ftsI基因中有突变(gBLNAR),20株仅产β-内酰胺酶(gBLPAR),15株既产β-内酰胺酶又在ftsI基因中有突变(gBLPACR)。按照当前的CLSI断点,大多数gBLNAR分离株通过微量稀释法(76.5%)或Etest法(88.2%)对氨苄西林敏感。通过微量稀释法检测时,大多数gBLNAR菌株(79.4%)对阿莫西林(在美国和欧洲最广泛使用的社区抗生素)不敏感。通过Etest法检测,15%的β-内酰胺酶阳性分离株对氨苄西林或阿莫西林不耐药。Etest法和微量稀释法结果之间一致性最差的是gBLPAR分离株(氨苄西林为25%,阿莫西林为15%,头孢克洛为10%)。低强度的氨苄西林和阿莫西林-克拉维酸纸片对低BLNAR分离株的鉴定效果不佳,不建议作为筛查方法。我们建议针对BLNAR分离株的新的阿莫西林断点如下:敏感,MIC≤0.5微克/毫升(无耐药机制;药代动力学/药效学[PK/PD]数据有利);中介,MIC为1至2微克/毫升(存在耐药机制但PK/PD数据有利),耐药,MIC≥4微克/毫升(存在耐药机制且PK/PD数据不利)。